Epirubicin
Fallopian Tube Cancer
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
OncoC4, Inc.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05446298CT.gov ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT05579366CT.gov Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | — | Recruiting | — | — | — |
NCT05200260CT.gov Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT04575961CT.gov Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT05092360CT.gov Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | — | Terminated | — | — | — |
NCT04375956CT.gov Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients | — | Unknown | — | — | — |
NCT04515602CT.gov Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | — | Not Yet Recruiting | — | — | — |
NCT03430700CT.gov Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer | — | Completed | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03740165CT.gov Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | — | Completed | — | — | — |
Show 13 more trialsShow fewer
NCT03621982CT.gov Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03180177CT.gov Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer | — | Unknown | — | — | — |
NCT03029403CT.gov Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
NCT03311334CT.gov A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT03126812CT.gov Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | — | Completed | — | — | — |
NCT02834975CT.gov Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | — | Terminated | — | — | — |
NCT02865811CT.gov Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | — | Completed | — | — | — |
NCT02520154CT.gov Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT02728830CT.gov A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | — | Completed | — | — | — |
NCT02657889CT.gov Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | — | Completed | — | — | — |
NCT02575807CT.gov Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer | — | Terminated | — | — | — |
NCT02606305CT.gov Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epirubicin (this asset) | OncoC4, Inc. | P3 | BB · 64 |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
| Adriamycin | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Carboplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Nogitecan | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | GOG Foundation | P3 | BB |
| Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | P3 | BB |
| Metformin | University of Chicago | P2 | BB |
+42 more in the Fallopian Tube Cancer cohort
Other indications for Epirubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Inflammatory Breast Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Epirubicin in Fallopian Tube Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/epirubicin-fallopian-tube-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →